What is Amycretin used for?
Amycretin is most commonly used for trial participants in obesity studies; followers of Novo's next-generation pipeline; educational reference for dual co-agonist design. Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide. Human evidence for Amycretin is limited, so these are the goals people pursue with it, not guaranteed outcomes.
What people use Amycretin for
- Trial participants in obesity studies
- Followers of Novo's next-generation pipeline
- Educational reference for dual co-agonist design
References
- Amycretin (Novo Nordisk), early Phase 1/2 obesity readouts — Novo Nordisk pipeline, 2024-2025
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Dahl K et al., The Lancet, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human, phase 1 trial — Gasiorek A et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Amycretin
Last updated 2026-06-15.